You are here
March 28, 2023
Woman potentially cured of HIV using transplant with cord blood stem cells
At a Glance
- A woman with leukemia is likely cured of HIV after receiving a transplant including stem cells from banked umbilical cord blood.
- The result suggests a way to expand the pool of available stem cells for curing HIV in people who require transplants for other medical conditions.
Three cases of HIV being cured have been reported to date. All three involved men with HIV and either leukemia or lymphoma. The men received transplants of stem cells from adult donors to treat their cancers. The stem cell donors all carried two copies of a mutation, CCR5 Δ32, that confers resistance to HIV. CCR5 is a receptor that HIV uses to infect cells. But very few people carry two copies of CCR5 Δ32, limiting the chances of finding a compatible donor, particularly for non-White patients.
A team led by Drs. Jingmei Hsu at Weill Cornell Medicine, Yvonne Bryson of the University of California, Los Angeles, and Deborah Persaud of the Johns Hopkins University School of Medicine used a modified approach to try to cure HIV. Their patient was a middle-aged woman who self-identified as mixed-race and had both HIV and fast-progressing, or acute, leukemia. Because of the difficulty in finding a compatible adult donor, the transplant included stem cells from banked umbilical cord blood. Umbilical cord blood stem cells don’t need as close a match for successful transplant as adult stem cells. If successful, this approach could expand the pool of CCR5 Δ32 stem cells available to those living with HIV.
The researchers obtained cord blood stem cells with two CCR5 Δ32 mutations that were a partial match for the patient. A challenge with transplanting cord blood stem cells is that it takes time for the cells to engraft in the body. So, the researchers infused the cord blood cells alongside stem cells from a relative of the patient. These did not carry the CCR5 Δ32 mutation but were partially compatible with the patient. In this type of transplant, the adult stem cells engraft quickly, but temporarily. This allows them to provide some immune function until the cord blood cells have a chance to take over. Results appeared in Cell on March 16, 2023.
As expected, the relative’s stem cells engrafted quickly, within two weeks of transplant. But by 14 weeks after transplant, the cord blood cells had completely taken over. A major risk associated with stem cell transplants is graft-versus-host disease—when transplanted immune cells attack the recipient’s body. But cord blood cells are less likely to do so and, in this case, the patient did not develop graft-versus-host disease.
The patient’s leukemia remains in remission more than five years after the transplant. Before the transplant, she controlled her HIV infection with antiretroviral drugs, but some HIV genetic material was still detectable. After transplant, no HIV DNA or RNA were detected. By a year after the transplant, she no longer had antibodies against HIV, which suggests HIV was no longer replicating in her body. Also, after the transplant, the stem cells in her blood resisted infection by various HIV strains in the lab.
About three years after the transplant, the patient stopped antiretroviral therapy. At the time the study results were written, 18 months after stopping treatment, the patient remained free of HIV infection. The researchers say she has now remained free of infection for nearly 30 months.
These results suggest that the cord blood stem cell transplant may have cured the patient of HIV. This would make her one of only four such patients, and the first woman to be so cured. Stem cell transplant remains a complex and risky procedure. It is only considered in people who need one to treat a life-threatening condition, such as leukemia—not to treat HIV alone. Even so, in people with HIV who do need a transplant, using cord blood stem cells could expand access to this treatment.
“It’s exceedingly rare for persons of color or diverse race to find a sufficiently matched, unrelated adult donor,” Bryson says. “Using cord blood cells broadens the opportunities for people of diverse ancestry who are living with HIV and require a transplant for other diseases to attain cures.”
—by Brian Doctrow, Ph.D.
Editor's Note: The headline and first bullet were modified soon after publication to better reflect the focus of the story.
- New Strategies Drive HIV From Cellular Hiding Places
- Antibody Combination Suppresses HIV
- Engineered Antibody Protects Monkeys From HIV-Like Virus
- Dual Antibody Treatment Suppresses HIV-Like Virus in Monkeys
- Sustained SIV Remission Achieved in Monkeys
- Benefits of Early Antiretroviral Therapy in HIV Infection
- HIV Immunotherapy Promising in First Human Study
- HIV and AIDS: Know the Facts
References: HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Hsu J, Van Besien K, Glesby MJ, Pahwa S, Coletti A, Warshaw MG, Petz L, Moore TB, Chen YH, Pallikkuth S, Dhummakupt A, Cortado R, Golner A, Bone F, Baldo M, Riches M, Mellors JW, Tobin NH, Browning R, Persaud D, Bryson Y; International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) P1107 Team. Cell. 2023 Mar 16;186(6):1115-1126.e8. doi: 10.1016/j.cell.2023.02.030. PMID: 36931242.
Funding: NIH’s National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and National Institute of Mental Health (NIMH).